2014 shaping up to be bridge year for Lilly

Share this article:
Lilly Alimta patent extended to 2022
Lilly Alimta patent extended to 2022

Eli Lilly confirmed that 2014 will be a roughly $20-billion revenue year—though it may be through a skin-of-its-teeth scenario.

“We expect 2014 to be the most financially challenging year of Lilly's current patent expirations,” CFO Derica Rice said in a statement, noting that the company is just beginning to come to grips with a patent-free Cymbalta landscape—the depression drug went off-patent in December—while also preparing for the osteoporosis med Evista's slide from protected IP to generic free-for-all in March.

The company pegged revenues as between $19.2 billion and $19.8 billion, vs. consensus, which Bernstein analyst Tim Anderson wrote in a Jan. 7 research note is between $19.5 billion and $19.8 billion.

Despite the immediate pain, Rice said the company is “positioned to return to growth and expand margins in 2015 and beyond.”

The company has previously said that its drive to the $20-billion mark will likely take a bit of grit, along the lines of finding efficiencies. Anderson wrote Tuesday that Lilly and investors knew 2014 was going to be a rough patch, but he, like Leerink Swann's Seamus Fernandez, sees reasons to keep the company in mind because the Indianapolis, IN, drugmaker “will be a very catalyst-laden story” in 2014.

Cutting R&D by around $1 billion is among the efforts Lilly's using to close in on this year's earnings target. The company said the drawdown is because its mature Phase III pipeline and near-mature products need less investment.

Share this article:

Email Newsletters

More in News

Eli Lilly and BI's Jardiance hits shelves

Eli Lilly and BI's Jardiance hits shelves

The new SGLT-2 inhibitor is on shelves less than a month after FDA approval.

PhRMA Urges Court to Reject Off-Label Promotion Case

PhRMA Urges Court to Reject Off-Label Promotion Case

The Pharmaceutical Research and Manufacturers of America (PhRMA) says a California federal court should dismiss a whistleblower's False Claims Act suit against three drug companies on First Amendment grounds

Five things for Pharma Marketers to know: Tuesday, August 26

Five things for Pharma Marketers to know: Tuesday, ...

Merck and Pfizer pursue new pembrolizumab research, black box warnings are linked to fewer court visits, and the WHO says it needs $430M to fight Ebola.